根据名称进行药物检索

Zantac (Ranitidine Injection)与肾功能不全

Zantac (Ranitidine Injection)与肾功能不全安全配伍检测的结果。

检测结果:

Zantac (Ranitidine Injection) <> 肾功能不全

现实性: 23.07.2019 评论家: 医学副博士Shkutko P.M., in

通过权威的信息来源 Drugs.com、Rxlist.com、Webmd.com、Medscape.com，在进行所选药物与这种伴发疾病互相作用检测时，发现一些会产生负面影响或对身体危害的禁忌症及副作用。

用户:

此药物的主要是消除肾脏。虽然药物是一般的容忍，每日的剂量最初应可减少在患有中等至严重肾损伤(肌酐清除率<50毫升/分钟)。如果有必要，每日的剂量可能会增加小心谨慎。

来源

McFayden ML, Folb PI, Miller R, et al "Pharmacokinetics of ranitidine in patients with chronic renal failure." Eur J Clin Pharmacol 25 (1983): 347-51
Meffin PJ, Grgurinovich N, Brooks PM, et al "Ranitidine disposition in patients with renal impairment." Br J Clin Pharmacol 16 (1983): 731-4
Kopitar Z, Cvelbar P, Zorz M, et al "Pharmacokinetics of ranitidine in adult patients with end stage renal disease after single and multiple dosing." Acta Pharm Juglosl 37 (1987): 371-9
Garg DC, Baltodano N, Jallad NS, et al "Pharmacokinetics of ranitidine in patients with renal failure." J Clin Pharmacol 26 (1986): 286-91
Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994): 393-408
McGonigle RJ, Williams LC, Amphlett GE, et al "The pharmacokinetics of ranitidine in renal disease." Pharmacokinet Pharmacodynam (1982): 41-7
Dixon JS, Borgcostanzi JM, Langley SJ, Lacey LF, Toon S "The effect of renal function on the pharmacokinetics of ranitidine." Eur J Clin Pharmacol 46 (1994): 167-71
"Product Information. Zantac (ranitidine)." Glaxo Wellcome, Research Triangle Park, NC.
Zech PY, Chau NP, Pozet N, et al "Ranitidine kinetics in chronic renal impairment." Clin Pharmacol Ther 34 (1983): 667-72

Zantac (Ranitidine Injection)

非专利名称: ranitidine

品牌: Zantac

同义词: Zantac

Zantac (Ranitidine Injection)是什么？